title: Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells.
abstract: We have previously demonstrated that expression of the novel gene schlafen-3 (Slfn-3) correlates with intestinal epithelial cell differentiation (Patel VB, Yu Y, Das JK, Patel BB, Majumdar AP. Biochem Biophys Res Commun 388: 752-756, 2009). The present investigation was undertaken to examine whether Slfn-3 plays a role in regulating differentiation of FOLFOX-resistant (5-fluorouracil + oxaliplatin) colon cancer cells that are highly enriched in cancer stem cells (CSCs). Transfection of Slfn-3 in FOLFOX-resistant colon cancer HCT-116 cells resulted in increase of alkaline phosphatase activity, a marker of intestinal differentiation. Additionally, Slfn-3 transfection resulted in reduction of mRNA and protein levels of the CSC markers CD44, CD133, CD166, and aldehyde dehydrogenase 1 in both FOLFOX-resistant HCT-116 and HT-29 cells. This was accompanied by decreased formation of tumorosphere/colonosphere (an in vitro model of tumor growth) in stem cell medium and inhibition of expression of the chemotherapeutic drug transporter protein ABCG2. Additionally, Slfn-3 transfection of FOLFOX-resistant HCT-116 and HT-29 cells reduced Hoechst 33342 dye exclusion. Finally, Slfn-3 transfection inhibited the expression of transforming growth factor-α in both FOLFOX-resistant colon cancer cells, but stimulated apoptosis in response to additional FOLFOX treatment. In summary, our data demonstrate that Slfn-3 expression inhibits multiple characteristics of CSC-enriched, FOLFOX-resistant colon cancer cells, including induction of differentiation and reduction in tumorosphere/colonosphere formation, drug transporter activity, and autocrine stimulation of proliferation. Thus Slfn-3 expression may render colon CSCs more susceptible to cancer chemotherapeutics.
authors: Veterans Affairs Medical Center, Wayne State University, Detroit, Michigan, USA.
authors: Phil-Sun
authors: PS
authors: Oh
authors: Vaishali B
authors: VB
authors: Patel
authors: Matthew A
authors: MA
authors: Sanders
authors: Shailender S
authors: SS
authors: Kanwar
authors: Yingjie
authors: Y
authors: Yu
authors: Jyoti
authors: J
authors: Nautiyal
authors: Bhaumik B
authors: BB
authors: Patel
authors: Adhip P N
authors: AP
authors: Majumdar
references: J Immunol Methods. 2009 Aug 15;347(1-2):70-8
references: 19567251
references: Cancer Res. 2007 Jan 15;67(2):827-35
references: 17234795
references: Cancer Biol Ther. 2007 Sep;6(9):1490-5
references: 17881904
references: J Mol Histol. 2004 Mar;35(3):211-31
references: 15339042
references: Nat Rev Cancer. 2002 Jan;2(1):48-58
references: 11902585
references: Clin Cancer Res. 2008 Nov 1;14(21):6751-60
references: 18980968
references: Int Immunol. 2004 Oct;16(10):1535-48
references: 15351786
references: J Biol Chem. 2005 Sep 2;280(35):30723-34
references: 15946944
references: Clin Ther. 2005 Jan;27(1):23-44
references: 15763604
references: Biochem Biophys Res Commun. 2009 Oct 30;388(4):752-6
references: 19703412
references: Nature. 1985 Feb 28-Mar 6;313(6005):745-7
references: 3883191
references: Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63
references: 17548814
references: CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
references: 11577478
references: N Engl J Med. 2006 Sep 21;355(12):1253-61
references: 16990388
references: Stem Cells. 2004;22(7):1142-51
references: 15579635
references: Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70
references: 9861027
references: Cancer Res. 2008 Dec 15;68(24):10051-9
references: 19074870
references: Nat Rev Cancer. 2005 Apr;5(4):275-84
references: 15803154
references: Cancer Res. 2003 Jul 1;63(13):3819-25
references: 12839979
references: Nat Med. 1997 Dec;3(12):1337-45
references: 9396603
references: J Cell Biochem. 2009 Jul 1;107(4):639-54
references: 19479902
references: Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G381-7
references: 16093419
references: Exp Mol Pathol. 2007 Oct;83(2):207-15
references: 17599831
references: FASEB J. 1992 Sep;6(12):3039-50
references: 1521737
references: Cell. 2007 Feb 9;128(3):445-58
references: 17289566
references: Cell Stem Cell. 2007 Nov;1(5):555-67
references: 18371393
references: Cancer Res. 2009 Mar 1;69(5):1951-7
references: 19244128
references: Blood. 2008 Dec 15;112(13):4793-807
references: 19064739
references: Am J Physiol Gastrointest Liver Physiol. 2010 Jun;298(6):G994-G1003
references: 20299602
references: Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G955-62
references: 19228883
references: Int J Oncol. 2000 Jul;17(1):141-7
references: 10853031
references: Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G396-403
references: 12672650
references: Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
references: 7612182
references: FASEB J. 2007 Dec;21(14):3777-85
references: 17625071
references: Pharm Res. 2011 Apr;28(4):827-38
references: 21161336
references: Biochem Biophys Res Commun. 2008 May 23;370(1):62-6
references: 18355440
references: J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011
references: 17979879
references: Nat Rev Cancer. 2007 Aug;7(8):573-84
references: 17625587
references: Cancer Res. 2009 Oct 15;69(20):8208-15
references: 19808966
references: J Clin Pharmacol. 2005 Aug;45(8):872-7
references: 16027397
references: Gastroenterology. 2008 Mar;134(3):849-64
references: 18325394
references: Transl Oncol. 2009 Dec;2(4):321-8
references: 19956394
references: N Engl J Med. 1980 Oct 9;303(15):878-80
references: 7412807
references: Mol Cancer. 2010 Aug 06;9:212
references: 20691072
references: Cell Stem Cell. 2007 Oct 11;1(4):389-402
references: 18371377